Oral adjuvant therapy for colorectal cancer: recent developments and future targets

Ther Deliv. 2019 Oct;10(10):659-669. doi: 10.4155/tde-2019-0067. Epub 2019 Nov 8.

Abstract

Colorectal cancer is considered the third most frequent malignant neoplasm occurring in both men and women worldwide. Most approaches that have been used to fight and treat this type of malignancy are either invasive or nonselective. Noninvasive therapy using oral route can increase patient compliance and reduce treatment costs. Innovative measures such as use of nanotechnology and theranostic systems have been initiated in the oral therapy, which has been proven to be greatly advantageous in decreasing side effects, improving detection and diagnoses. This manuscript investigates recent innovative and novel therapeutic approaches through oral route and potential targets in the treatment of colorectal cancer.

Keywords: colorectal cancer; immunotherapy; monoclonal antibodies; nanotechnology; oral chemotherapy; targeted therapy; theranostic systems.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Chemotherapy, Adjuvant / methods
  • Colon / pathology
  • Colon / surgery
  • Colorectal Neoplasms / immunology
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / therapy*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Gastrointestinal Absorption
  • Humans
  • Medication Adherence
  • Neoplasm Staging
  • Randomized Controlled Trials as Topic
  • Rectum / pathology
  • Rectum / surgery
  • Theranostic Nanomedicine / methods*
  • Theranostic Nanomedicine / trends
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological